Deacon CF, Holst JJ (2002) Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective. Biochem Biophys Res Commun 294(1):1–4

Article  CAS  PubMed  Google Scholar 

Ceriello A, Sportiello L, Rafaniello C, Rossi F (2014) DPP-4 inhibitors: pharmacological differences and their clinical implications. Expert Opin Drug Saf 13(Suppl 1):S57-68

Article  PubMed  Google Scholar 

Filippatos TD, Athyros VG, Elisaf MS (2014) The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. Expert Opin Drug Metab Toxicol 10(6):787–812

Article  CAS  PubMed  Google Scholar 

Shafrir E, Raz I (2003) Diabetes: mellitus or lipidus? Diabetologia 46(3):433–440

Article  CAS  PubMed  Google Scholar 

Björntorp P, Shafrir E, Raz I (2003) For debate. Diabetes: mellitus or lipidus? Diabetologia 46(11):1586–1587

Article  PubMed  Google Scholar 

Hermans MP, Ahn SA, Rousseau MF (2021) Lipid and cardiometabolic features of T2DM patients achieving stricter LDL-C and non-HDL-C targets in accordance with ESC/EAS 2019 guidelines. Acta Cardiol 76(4):375–383

Article  PubMed  Google Scholar 

Kutoh E, Kaneoka N, Hirate M (2015) Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties. Endocr Res 40(2):88–96. https://doi.org/10.3109/07435800.2014.952743. (Epub 2014 Sep 10 PMID: 25208188)

Article  CAS  PubMed  Google Scholar 

Carpentier AC (2021) 100th anniversary of the discovery of insulin perspective: insulin and adipose tissue fatty acid metabolism. Am J Physiol Endocrinol Metab 320(4):E653–E670

Article  CAS  PubMed  Google Scholar 

Girard J (2003) Rôle des acides gras libres dans la sécrétion et l’action de l’insuline: mécanismes de la lipotoxicité [Contribution of free fatty acids to impairment of insulin secretion and action: mechanism of beta-cell lipotoxicity]. Med Sci (Paris) 19(8–9):827–833

Article  PubMed  Google Scholar 

Kutoh E, Wada A, Hayashi J (2018) Regulation of free fatty acid by sitagliptin monotherapy in drug-naïve subjects with type 2 diabetes. Endocr Pract 24(12):1063–1072

Article  PubMed  Google Scholar 

Kim JY, Bacha F, Tfayli H, Michaliszyn SF, Yousuf S, Arslanian S (2019) Adipose tissue insulin resistance in youth on the spectrum from normal weight to obese and from normal glucose tolerance to impaired glucose tolerance to type 2 diabetes. Diabetes Care 42(2):265–272

Article  CAS  PubMed  Google Scholar 

Gastaldelli A, Gaggini M, DeFronzo RA (2017) Role of adipose tissue insulin resistance in the natural history of type 2 diabetes: results from the San Antonio Metabolism Study. Diabetes 66(4):815–822

Article  PubMed  Google Scholar 

Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K (2009) Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50(4):1087–1093

Article  CAS  PubMed  Google Scholar 

Kutoh E, Kuto AN, Wada A, Kurihara R, Kojima R (2021) Complementary effects on glycaemic and non-glycaemic parameters between responders and non-responders treated with pioglitazone and canagliflozin in drug-naive subjects with type 2 diabetes. Int J Clin Pract 75(12):e14914

Article  CAS  PubMed  Google Scholar 

Kutoh E, Kuto AN, Wada A, Kurihara R, Kojima R (2022) Regulations of free fatty acids and diabetic parameters in drug naïve subjects with type 2 diabetes treated with canagliflozin monotherapy. Drug Res (Stuttg) 72(2):86–93

Article  CAS  PubMed  Google Scholar 

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419

Article  CAS  PubMed  Google Scholar 

Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85(7):2402–2410

Article  CAS  PubMed  Google Scholar 

Saisho Y, Kou K, Tanaka K, Abe T, Kurosawa H, Shimada A, Meguro S, Kawai T, Itoh H (2011) Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocr J 58(4):315–322

Article  CAS  PubMed  Google Scholar 

Amrhein V, Korner-Nievergelt F, Roth T (2017) The earth is flat (p > 0.05): significance thresholds and the crisis of unreplicable research. PeerJ 5:e3544

Article  PubMed  PubMed Central  Google Scholar 

Hermans MP, Ahn SA, Rousseau MF (2010) log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males. Cardiovasc Diabetol 14(9):88

Article  Google Scholar 

Hermans MP, Ahn SA, Rousseau MF (2012) The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females. Lipids Health Dis 11:132

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Takayama S, Abe M, Katoh T, Ohtsuka N (2011) Relationships between lipid profiles and metabolic syndrome, insulin resistance and serum high molecular adiponectin in Japanese community-dwelling adults. Lipids Health Dis 10:79

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sano M (2019) Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk. J Cardiol 73(1):28–32

Article  PubMed  Google Scholar 

White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, EXAMINE Investigators (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369(14):1327–1335

Article  CAS  PubMed  Google Scholar 

Ueki K, Tanizawa Y, Nakamura J, Yamada Y, Inagaki N, Watada H, Shimomura I, Nishimura R, Miyoshi H, Abiko A, Katagiri H, Hayashi M, Shimada A, Naruse K, Fujimoto S, Fujiwara M, Shikata K, Okada Y, Araki E, Yamazaki T, Kadowaki T, J-BRAND Registry Group (2021) Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry). BMJ Open Diabetes Res Care 9(1):e001787

Article  PubMed  PubMed Central  Google Scholar 

Okada K, Kikuchi S, Kuji S, Nakayama N, Maejima N, Matsuzawa Y, Iwahashi N, Kosuge M, Ebina T, Kimura K, Tamura K, Hibi K (2022) Impact of early intervention with alogliptin on coronary plaque regression and stabilization in patients with acute coronary syndromes. Atherosclerosis 360:1–7

Article  CAS  PubMed  Google Scholar 

Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R, Sun Q, Mihai G, Maiseyeu A, Rajagopalan S (2011) Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 124(21):2338–2349

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amigo L, Husche C, Zanlungo S, Lütjohann D, Arrese M, Miquel JF, Rigotti A, Nervi F (2011) Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice. Liver Int 31(1):52–64

Article  CAS  PubMed  Google Scholar 

Bush NC, Triay JM, Gathaiya NW, Hames KC, Jensen MD (2014) Contribution of very low-density lipoprotein triglyceride fatty acids to postabsorptive free fatty acid flux in obese humans. Metabolism 63(1):137–140

Article  CAS  PubMed  Google Scholar 

Tsushima Y, Nishizawa H, Tochino Y, Nakatsuji H, Sekimoto R, Nagao H, Shirakura T, Kato K, Imaizumi K, Takahashi H, Tamura M, Maeda N, Funahashi T, Shimomura I (2013) Uric acid secretion from adipose tissue and its increase in obesity. J Biol Chem 288(38):27138–27149

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boersma GJ, Johansson E, Pereira MJ, Heurling K, Skrtic S, Lau J, Katsogiannos P, Panagiotou G, Lubberink M, Kullberg J, Ahlström H, Eriksson JW (2018) Altered glucose uptake in muscle, visceral adipose tissue, and brain predict whole-body insulin resistance and may contribute to the development of type 2 diabetes: a combined PET/MR study. Horm Metab Res 50(8):627–639

Article  CAS  PubMed  Google Scholar